Menstruation Disturbances Clinical Trial
Official title:
Tamoxifen for the Treatment of Unfavorable Bleeding Patterns in Etonogestrel Contraceptive Implant Users
The purpose of this study is to study whether a drug called tamoxifen can reduce vaginal bleeding in women who are using the Etonogestrel contraceptive implant.
Nearly all of the 3 million unintended pregnancies in the United States each year result from inconsistent or non-use of contraception. Increasing use of the most effective methods of contraception will reduce unintended pregnancies and their social, medical and economic consequences. The contraceptive etonogestrel implant (ENG implant) is 20 times more effective at pregnancy prevention than oral contraceptive pills, but it has bleeding side effects that make it unappealing for many women. Tamoxifen, a selective estrogen receptor modulator (SERM) used most commonly for adjuvant treatment of breast cancer, has previously been shown to dramatically reduce bleeding in users of an older levonorgestrel-based contraceptive implant (Norplant tm). It has not been studied in newer progestin-based methods such as the ENG implant. If tamoxifen could stop bleeding in users of the ENG implant, it would give patients and physicians a valuable option for management of progestin-induced irregular bleeding. This research project will test the effectiveness of tamoxifen taken on an as-needed basis to treat abnormal bleeding in ENG implant users. If tamoxifen can be established as an effective treatment for frequent or prolonged bleeding, it will increase the acceptability of the ENG implant, increase its use and reduce unintended pregnancies. This is the first project to evaluate tamoxifen for treatment of unfavorable bleeding in users of the ENG contraceptive implant. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00195559 -
Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder
|
Phase 3 | |
| Not yet recruiting |
NCT05948358 -
The Menstrual Distress Questionnaire (MEDI-Q) Reliability and Validity of the Turkish Version
|
||
| Terminated |
NCT01183377 -
Frequency of Female Athlete Triad Among Elite Female Athlete of Iran in Different Sport in 2007
|
N/A | |
| Not yet recruiting |
NCT04583943 -
Lifestyle Influence on Primary Dysmenorrhea
|
||
| Completed |
NCT05928650 -
Comparison of Menstrual Function Among Sprinters, Long Marathon Runners, and Non-Athletic Females
|
||
| Completed |
NCT04938622 -
Bioenergetics of Exercise-Induced Menstrual Disturbances
|
N/A | |
| Completed |
NCT05107804 -
Energy Restriction and Hormones in Premenopausal Women
|
N/A | |
| Recruiting |
NCT06297980 -
Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT01103518 -
Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation
|
Phase 4 | |
| Completed |
NCT00128934 -
Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder
|
Phase 3 | |
| Completed |
NCT00001259 -
A Treatment Study for Premenstrual Syndrome (PMS)
|
Phase 1 | |
| Completed |
NCT02486757 -
Investigation of Female Reproductive Hormone Dynamics During Adolescence
|
Early Phase 1 | |
| Withdrawn |
NCT00357981 -
Continuous Use of the Contraceptive Patch and the Personal Economic Impact.
|
N/A |